SQZ Biotechnologies Profit Margin 2020-2022 | SQZ

Current and historical gross margin, operating margin and net profit margin for SQZ Biotechnologies (SQZ) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. SQZ Biotechnologies net profit margin as of September 30, 2022 is -355.2%.
SQZ Biotechnologies Annual Profit Margins
SQZ Biotechnologies Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.023B $0.027B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $151.446B 9.24
GSK (GSK) United Kingdom $72.652B 9.59
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.227B 19.16
Ginkgo Bioworks Holdings (DNA) United States $3.880B 0.00
Myovant Sciences (MYOV) United Kingdom $2.615B 0.00
Arcus Biosciences (RCUS) United States $1.620B 24.32
Biohaven (BHVN) United States $1.283B 0.00
Emergent Biosolutions (EBS) United States $0.681B 5.35
ADC Therapeutics SA (ADCT) Switzerland $0.419B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.066B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00